{"pmid":32281653,"title":"Reply to: \"Reporting of all cardiac medications and their outcome in COVID-19\".","text":["Reply to: \"Reporting of all cardiac medications and their outcome in COVID-19\".","We thank Dr. Ajay Kumar Mishra and his colleagues for their attention to our review.(1, 2) We strongly agree with them that it is inappropriate for COVID-19 patients to discontinue ACEIs /ARBs without weighing up the pros and cons.(3, 4) Whether the RAAS inhibitors may affect the prognosis of COVID-19 patients still needs more clinical trials to confirm. This article is protected by copyright. All rights reserved.","J Med Virol","Cheng, Hao","Wang, Yan","Wang, Gui-Qiang","32281653"],"abstract":["We thank Dr. Ajay Kumar Mishra and his colleagues for their attention to our review.(1, 2) We strongly agree with them that it is inappropriate for COVID-19 patients to discontinue ACEIs /ARBs without weighing up the pros and cons.(3, 4) Whether the RAAS inhibitors may affect the prognosis of COVID-19 patients still needs more clinical trials to confirm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Cheng, Hao","Wang, Yan","Wang, Gui-Qiang"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281653","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25868","source":"PubMed","weight":0,"_version_":1663989232607166464,"score":7.979339,"similar":[{"pmid":32232977,"title":"Response to \"Comments on 'Zhang et al.: Clinical trial analysis of 2019-nCoV therapy registered in China '\".","text":["Response to \"Comments on 'Zhang et al.: Clinical trial analysis of 2019-nCoV therapy registered in China '\".","We thank Dr. Yang and colleagues for their attention to our article(1,2) . And we appreciate their meaningful suggestions, which we highly agree with. With the purpose of letting the public know the overall situation of the clinical trials of new coronary pneumonia in China as soon as possible, we completed the data collection and brief analysis in a very short time. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian","32232977"],"abstract":["We thank Dr. Yang and colleagues for their attention to our article(1,2) . And we appreciate their meaningful suggestions, which we highly agree with. With the purpose of letting the public know the overall situation of the clinical trials of new coronary pneumonia in China as soon as possible, we completed the data collection and brief analysis in a very short time. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232977","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25803","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1663352135418380289,"score":218.87798},{"pmid":32266993,"title":"Reporting of all cardiac medications and their outcome in COVID - 19.","text":["Reporting of all cardiac medications and their outcome in COVID - 19.","We read with much interest the article \"Organ- protective effect of Angiotensin Converting Enzyme 2 and its Effect on the prognosis of COVID -19\" by Cheng et al in your esteemed Journal. Authors have discussed the theoretical basis of Angiotensin Converting Enzyme 2 in improving outcome of COVID - 19 patients(1) . This article is protected by copyright. All rights reserved.","J Med Virol","Mishra, Ajay Kumar","Sahu, Kamal Kant","Lal, Amos","32266993"],"abstract":["We read with much interest the article \"Organ- protective effect of Angiotensin Converting Enzyme 2 and its Effect on the prognosis of COVID -19\" by Cheng et al in your esteemed Journal. Authors have discussed the theoretical basis of Angiotensin Converting Enzyme 2 in improving outcome of COVID - 19 patients(1) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Mishra, Ajay Kumar","Sahu, Kamal Kant","Lal, Amos"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266993","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25843","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663609715794378752,"score":157.19363},{"pmid":32228222,"title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.","text":["Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.","The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.","Emerg Microbes Infect","Meng, Juan","Xiao, Guohui","Zhang, Juanjuan","He, Xing","Ou, Min","Bi, Jing","Yang, Rongqing","Di, Wencheng","Wang, Zhaoqin","Li, Zigang","Gao, Hong","Liu, Lei","Zhang, Guoliang","32228222"],"abstract":["The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension."],"journal":"Emerg Microbes Infect","authors":["Meng, Juan","Xiao, Guohui","Zhang, Juanjuan","He, Xing","Ou, Min","Bi, Jing","Yang, Rongqing","Di, Wencheng","Wang, Zhaoqin","Li, Zigang","Gao, Hong","Liu, Lei","Zhang, Guoliang"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228222","week":"202014|Mar 30 - Apr 05","doi":"10.1080/22221751.2020.1746200","keywords":["COVID-19","Renin-angiotensin system","angiotensin II type1 receptor blockers","angiotensin-converting enzyme inhibitors","hypertension"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135406845952,"score":142.93596},{"pmid":32250244,"title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","text":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.","Elife","Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias","32250244"],"abstract":["The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population."],"journal":"Elife","authors":["Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250244","week":"202015|Apr 06 - Apr 12","doi":"10.7554/eLife.57278","keywords":["epidemiology","global health","viruses"],"source":"PubMed","locations":["ACE-1","AngII"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136227880961,"score":125.534805},{"pmid":32228252,"title":"COVID-19, ACE2 and the Cardiovascular Consequences.","text":["COVID-19, ACE2 and the Cardiovascular Consequences.","The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the co-receptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades Ang II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7) which antagonizes the effects of Ang II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, AT1 receptor antagonists and mineralocorticoid antagonists, as well as statins enhance ACE2 that, in part, contribute to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19.","Am J Physiol Heart Circ Physiol","South, Andrew Michael","Diz, Debra","Chappell, Mark C","32228252"],"abstract":["The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the co-receptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades Ang II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7) which antagonizes the effects of Ang II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, AT1 receptor antagonists and mineralocorticoid antagonists, as well as statins enhance ACE2 that, in part, contribute to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19."],"journal":"Am J Physiol Heart Circ Physiol","authors":["South, Andrew Michael","Diz, Debra","Chappell, Mark C"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228252","week":"202014|Mar 30 - Apr 05","doi":"10.1152/ajpheart.00217.2020","keywords":["ACE2","Angiotensin II","SARS-CoV-2","renin-angiotensn system","statins"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135355465728,"score":110.43217}]}